Neonatal Screening for Congenital Adrenal Hyperplasia in the Czech Republic - Results ofa One-year Pilot Study in Males
Authors:
F. Votava; P. Kračmar; V. Rákosníková; J. Lebl; O. Hníková; J. Brejchová; P. Vacková; R. Zatloukalová
Authors‘ workplace:
Klinika dětí a dorostu 3. LF UK a FN Královské Vinohrady, Praha, přednosta doc. MUDr. J. Lebl, CSc.
Published in:
Čes-slov Pediat 2002; (12): 690-696.
Category:
Overview
Congenital adrenal hyperplasia (CAH) is a potentially fatal inborn endocrine disease due to defective steroidsynthesis, the most prevalent being deficiency of the enzyme P450c21 (21-hydroxylase). Neonatal screening of CAHis based on measurement of 17--hydroxyprogesterone (17-OHP) in a dried blood spot. It makes possiblerecognition of the disease, prevention of metabolic crisis (salt-wasting SW) in patients and early introduction oftherapy with the virilizing (SV) form.The first year of the pilot study of neonatal screening of CAH in the Czech Republic was made in the laboratoryof neonatal screening of the University Hospital Prague - Kralovske Vinohrady from January 1st up to December31st, 2001, only in males.We analysed 26 502 dried blood spots (incl. 1431 from boys with birth weights less than2500 g). The 17-OHP concentration was measured using DELFIA (Neonatal 17-OH-progesterone kit,Wallac Oy,Turku, Finland). Additionally, the age at blood sampling and the period up to the delivery to the laboratory wereevaluated in 2718 newborns.A 17-OHP concentration over 30 nmol/l was recorded in 55 of 25 071 males with a birth weight of 2500 g ormore which led to a recall (recall rate 0.219 %). In males with a birth weight less than 2500 g, the recall rate was3.843% (55 of 1431) using weight adjusted cut off limits. A clearly positive 17-OHP concentration over 90 nmol/l(range, 108 - 760) was found in 7 boys (all birth weight over 2500 g). All were urgently admitted to hospital asurgent cases CAH was confirmed in 3 of them (once, SV; twice, SW; positive predictive value 0.43). The overageday of blood sampling was 5 (range 2 - 11) and period up to delivery to the laboratory 5 days (range 0 - 29) innewborns with birth weights over 2500 g, day 6 (2 - 32) and 5 days (0- 33) in subjects with birth weight 1500 - 2499g and day 8 (range 2 - 56) and 5 days (range 1 - 23) in subjects with birth weight less than 1500 g.The results of one year of the pilot study proved the feasibility and efficiency of the neonatal screening of CAHin the Czech Republic.
Key words:
congenital adrenal hyperplasia, neonatal screening, pilot study, 17-hydroxyprogesterone
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2002 Issue 12
Most read in this issue
- Clinical Course in 22 Children and Adultsfrom Central and Eastern Europe
- Subacute Panencephalitis in a 20-month Old Child
- Camurati-Engelmann’s Syndrome Imitation Muscular Dystrophy
- Neonatal Screening for Congenital Adrenal Hyperplasia in the Czech Republic - Results ofa One-year Pilot Study in Males